v3.26.3
Segment information - Significant Expenses by Segment (Details)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2026
USD ($)
segment
Sep. 30, 2025
USD ($)
segment
Sep. 30, 2026
USD ($)
segment
Sep. 30, 2025
USD ($)
segment
Segment and geographic information        
Number of operating segments | segment 1 1 1 1
Number of reportable segments | segment 1 1 1 1
Total revenues $ 357,807 $ 211,007 $ 990,877 $ 1,565,978
Acquired in-process research and development 111,000   111,000  
Net (loss) income attributable to common stockholders (51,693) 15,896 28,994 817,609
Income tax expense (benefit) 10,605 (38,970) 25,001 18,093
Amortization 12,595 7,534 36,017 15,393
Operating segments | Life Science        
Segment and geographic information        
Total revenues 357,807 211,007 990,877 1,565,978
Cost of product, collaboration and license sales 12,740 12,441 43,351 28,241
Program spend 39,275 45,940 119,400 143,803
Employee costs 65,245 64,470 209,714 197,762
Manufacturing costs 11,632 11,048 26,949 45,517
Administrative costs 22,982 18,614 56,221 54,924
Occupancy costs 7,195 7,852 23,042 21,678
Acquired in-process research and development 111,000   111,000  
Other segment items 139,431 34,746 372,206 256,444
Net (loss) income attributable to common stockholders (51,693) 15,896 28,994 817,609
Interest income (20,928) (19,089) (57,032) (57,325)
Interest expense 66,794 51,681 200,409 154,367
Income tax expense (benefit) 10,605 (38,970) 25,001 18,093
Depreciation 4,222 3,569 12,037 10,600
Amortization 12,595 7,534 36,017 15,393
All other 66,143 30,021 155,774 115,316
Total other segment items $ 139,431 $ 34,746 $ 372,206 $ 256,444